Captor Capital Reports Higher Revenues and Lower Expenses in Unaudited Interim Financial Statements for the Three Months Ended September 30, 2019

TORONTO, Dec. 02, 2019 (GLOBE NEWSWIRE) — Captor Capital Corp. (CSE: CPTR; FRANKFURT: NMV; STUTTGART: NMVA; USOTC: CPTRF), (“Captor” or the “Company”), an integrated cannabis company, today released its interim financial statements and quarterly MD&A for the three months ended September 30, 2019. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. The Company…

Read More

Captor Capital Announces Addition to Board of Directors

Captor Capital Corp

TORONTO, Nov. 21, 2019 (GLOBE NEWSWIRE) — Captor Capital Corp. (CSE: CPTR; FRANKFURT: NMV; STUTTGART: NMVA; USOTC: CPTRF), (“Captor” or the “Company”), an integrated cannabis company, today appointed Mark Klein to the Board of Directors as an Independent Director. Mr. Klein has almost two decades of senior level experience in all facets of start-ups, business strategy, and investment management. Mr.…

Read More

Captor Capital Announces Changes to Board of Directors

TORONTO, Nov. 12, 2019 (GLOBE NEWSWIRE) — Captor Capital Corp. (CSE: CPTR; FRANKFURT: NMV; STUTTGART: NMVA; USOTC: CPTRF), (“Captor” or the “Company”), an integrated cannabis company, today appointed Bryan Reyhani to the Board of Directors as an Independent Director. Mr. Reyhani has two decades of legal and business experience and has handled various investor, regulatory, financing, and corporate governance matters…

Read More

Captor Capital Resumes Trading on the OTCQX® Best Market

TORONTO, Nov. 11, 2019 (GLOBE NEWSWIRE) — Captor Capital Corp. (CSE: CPTR; FRANKFURT: NMV; STUTTGART: NMVA; USOTC: CPTRF), (“Captor” or the “Company”) (CSE: CPTR) is pleased to announce that the Company’s stock has resumed on the OTCQX® Best Market following a full revocation of the cease trade order previously issued against the Company Ontario Securities Commission (the “CTO”). The CTO…

Read More

Captor Capital Announces Corporate Update

TORONTO, Nov. 06, 2019 (GLOBE NEWSWIRE) — Captor Capital Corp. (CSE: CPTR; FRANKFURT: NMV; STUTTGART: NMVA; USOTC: CPTRF), (“Captor” or the “Company”) (CSE: CPTR) is pleased to announce that the Ontario Securities Commission has granted a full revocation of the cease trade order previously issued against the Company (the “CTO”). The CTO was issued as a result of the Company’s…

Read More

Captor Capital Announces Cease Trade Order Related to Delayed Filing of Financial Statements for the Year Ended March 31, 2019

TORONTO, Aug. 07, 2019 (GLOBE NEWSWIRE) — Captor Capital Corp. (CSE: CPTR; FRANKFURT: NMV; STUTTGART: NMVA; USOTC: CPTRF), (“Captor” or the “Company”), a cannabis-focused investment company, announced that a failure-to-file cease trade order has been issued by the securities regulators as of August 6, 2019 as a result of the previously announced delay in filing the Company’s annual audited financial…

Read More

Captor Capital Appoints Dene Rogers as CEO of Captor Acquisition Corp.

TORONTO, Aug. 06, 2019 (GLOBE NEWSWIRE) — Captor Capital Corp. (CSE: CPTR; FRANKFURT: NMV; STUTTGART: NMVA; USOTC: CPTRF), (“Captor” or the “Company”), a cannabis-focused investment company, is pleased to announce the appointment of highly experienced and successful business leader, Dene Rogers, as the CEO of Captor Acquisition Corp.. Captor Acquisition Corp. is a wholly owned subsidiary, under which Captor Capital…

Read More

Captor Capital to Delay Filing of Financial Statements for the Year Ended March 31, 2019

TORONTO, July 29, 2019 (GLOBE NEWSWIRE) — Captor Capital Corp. (CSE: CPTR) (OTCQX:CPTRF) (“Captor” or the “Company”) reports that it expects to be late in filing its audited financial statements and management’s discussion and analysis for the year ended March 31, 2019 (the “Annual Financial Filings”). Although the Company’s audit is progressing to completion, the Company’s auditors are still reviewing…

Read More

Cannabis Biotech Startup, Demetrix Raises $50 Million Series A

Demetrix is engaged as an Emeryville, CA-based biotechnology startup that is focused on the production of cannabinoids. Utilizing microorganisms like baker’s yeast and fermentation, along with advanced biotechnology procedures, Demetrix is able to produce complex ingredients at a very high purity without the excessive costs. The goal is to develop high-quality cannabinoids for the use in pharmaceuticals, supplements, consumer products,…

Read More

10 Cannabis ETFs to Play the Marijuana Boom

Cannabis stocks have had a great start through the first five months of 2019. As we enter the first full year of Canada’s recreational cannabis legalization and prepare for the “second wave” this October, investors have seen overall strong returns despite the early supply issues. In the U.S., more states continue to warm up to the idea of loosening cannabis…

Read More